Intra-Cellular Therapies Expands Pipeline with New Anti-Dementia Agent

 ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particularly in elderly populations.

Phase 1 single ascending dose and multiple ascending dose studies have been completed in healthy volunteers including elderly subjects > than 65 years of age.

Company plans to develop ITI-1284 for the treatment of behavioral disturbances in dementia, dementia-related psychosis, and certain depressive disorders in the elderly.

http://www.globenewswire.com/news-release/2021/02/24/2181303/0/en/Intra-Cellular-Therapies-Announces-Expansion-of-its-Pipeline-with-the-Introduction-of-a-New-Molecular-Entity-ITI-1284.html